生活质量：患者的关键方面，CKD 患者贫血治疗中被忽视的目标。
Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD.
机构信息
Past Director, Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, Lecco, Italy.
Department of Nephrology and Dialysis, Sant' Anna Hospital, ASST Lariana, Como, Italy.
出版信息
Kidney Int. 2023 Jun;103(6):1025-1027. doi: 10.1016/j.kint.2023.03.026.
The aim of any treatment should be to add life to years and not simply years to life. Surprisingly, the label of erythropoiesis-stimulating agents for anemia treatment in chronic kidney disease does not include the indication for improving quality of life. Merit of the placebo-controlled Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) trial was to address this issue by analyzing the effect of anemia treatment with daprodustat aimed at the hemoglobin target range of 11-12 g/dl; the trial demonstrates that partial anemia correction improved quality of life.
任何治疗的目的都应该是延长生命的质量，而不仅仅是延长生命的长度。令人惊讶的是，红细胞生成刺激剂用于治疗慢性肾脏病贫血的标签并不包括改善生活质量的适应症。安慰剂对照的慢性肾脏病贫血研究（CKD）中的 Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor（PHI）Daprodustat 在非透析患者中评估血红蛋白（Hgb）和生活质量（ASCEND-NHQ）试验的优势在于通过分析以 11-12g/dl 血红蛋白靶目标范围为目的的用 daprodustat 治疗贫血的效果来解决这个问题；该试验表明，部分纠正贫血可以改善生活质量。
Zotero 插件